Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Table 3 Pearson correlation analysis among sleep scores (pooled data)

	MOS-Sleep Scale, SPI-I	UPDD Sleep Interference Score	CU-Q₂oL Sleep Problems domain
Sleep outcome
Baseline
MOS-Sleep Scale, SPI-I
r	1.00000	0.39454*	0.74655*
n	970	970	847
UPDD Weekly Sleep Interference Score
r	0.39454*	1.00000	0.48848*
n	970	975	848
CU-Q₂oL Sleep Problems domain
r	0.74655*	0.48848*	1.00000
n	847	848	848
Week 12
MOS-Sleep Scale, SPI-I
r	1.00000	0.44790*	0.72307*
n	828	809	722
UPDD Weekly Sleep Interference Score
r	0.44790*	1.00000	0.60849*
n	809	827	707
CU-Q₂oL Sleep Problems domain
r	0.72307*	0.60849*	1.00000
n	722	707	724
Week 24
MOS-Sleep Scale, SPI-I
r	1.00000	0.462952*	0.68932*
n	494	475	435
UPDD Weekly Sleep Interference Score
r	0.46295*	1.00000	0.58334*
n	475	726	418
CU-Q₂oL Sleep Problems domain
r	0.68932*	0.58334*	1.00000
n	435	418	437

CU-Q ₂ oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
* p < 0.0001